What it's for (Indications)
- Levamisole, historically associated with brands such as Ketress 40 mg, was primarily indicated as an adjuvant therapy in combination with fluorouracil for the postsurgical treatment of patients with Duke's C (Stage III) colon cancer.
- This therapeutic approach aimed to reduce the risk of recurrence following surgical resection of the primary tumor, leveraging levamisole's proposed immunomodulatory properties to enhance the host's immune response against residual malignant cells.
- While this specific indication was a significant treatment modality in its era, contemporary clinical guidelines and therapeutic practices have largely transitioned to newer, often more efficacious and less toxic, treatment regimens for colon cancer.
- Therefore, its use in this capacity is now considered largely historical in many regions.
- Beyond its immunomodulatory role, levamisole also possesses anthelmintic properties and has been utilized for the treatment of certain nematode infections, such as ascariasis and hookworm, though this particular application is distinct from the primary context suggested by the 'Ketress' branding.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For its historical indication as adjuvant therapy in Duke's C colon cancer, levamisole (e.g., Ketress 40 mg) was typically administered orally in a cyclical regimen alongside fluorouracil. A common dosing schedule involved an initial loading phase of 50 mg orally every 8 hours for 3 days, commencing approximately 7 to 30 days post-surgical resection. Following this initial course, patients would then proceed with maintenance doses of 50 mg orally every 8 hours for 3 days, repeated every 2 weeks, for a total treatment duration of 1 year. The precise integration of levamisole dosing with the fluorouracil regimen was critical and required careful adjustment based on the patient's individual tolerance, with particular attention to hematologic parameters. Due to the high risk of severe adverse reactions, especially myelosuppression, strict adherence to the prescribed dosing schedules and meticulous monitoring of complete blood counts were absolutely paramount. Dosage modifications or temporary interruptions were frequently implemented based on evolving laboratory results and comprehensive clinical assessment. |
Safety & Warnings
Common Side Effects
- Levamisole is associated with a comprehensive spectrum of side effects, several of which can be severe and potentially life-threatening.
- The most critical adverse effect is significant hematologic toxicity, predominantly manifesting as severe neutropenia and agranulocytosis, which mandates stringent and frequent monitoring of complete blood counts throughout therapy.
- Common gastrointestinal disturbances include nausea, vomiting, diarrhea, abdominal pain, stomatitis, and taste disturbances, often exacerbated when levamisole is co-administered with fluorouracil.
- Neurological adverse reactions can encompass dizziness, headache, fatigue, insomnia, confusion, and peripheral neuropathy; in rare but serious instances, encephalopathy has been reported.
- Dermatologic manifestations may include skin rash, pruritus, and alopecia.
- Patients may also experience systemic symptoms akin to a flu-like illness, such as fever, chills, and malaise, along with generalized asthenia.
- Less frequently observed but serious effects include vasculitis and pancreatitis.
- The potential for these significant adverse events, particularly agranulocytosis, underscores the necessity for vigilant patient monitoring and prompt intervention.
Serious Warnings
- Black Box Warning: **AGRANULOCYTOSIS AND NEUTROPENIA:** Levamisole is critically associated with a significant and potentially fatal risk of agranulocytosis and severe neutropenia, particularly when utilized in its immunomodulatory capacity, such as for adjuvant colon cancer therapy. This severe hematologic toxicity manifests as a precipitous and profound decline in the total white blood cell count, specifically affecting neutrophils, which renders the patient highly vulnerable to severe and potentially life-threatening infections. The onset of agranulocytosis can be abrupt and unpredictable, often occurring several weeks into the therapeutic regimen or even after cessation of treatment. Due to this severe and unremitting risk, all patients receiving levamisole must undergo rigorous and frequent monitoring of their complete blood count (CBC) with a differential, typically performed weekly during the initial phases of treatment and consistently thereafter. Treatment must be immediately and permanently discontinued at the first indication of a significant decrease in neutrophil count (e.g., to below 1000 cells/mm³) or upon the development of clinical symptoms suggestive of infection or agranulocytosis (e.g., unexplained fever, chills, sore throat, or malaise). Re-challenge with levamisole following such an event is strictly contraindicated. Patients and their caregivers must be thoroughly educated on these formidable risks and explicitly instructed to promptly report any signs or symptoms of infection or unusual bleeding/bruising to their healthcare provider. This boxed warning underscores the imperative for exceptionally vigilant patient management and consistent laboratory surveillance.
- Levamisole carries profound warnings, primarily stemming from its significant potential for severe hematologic and neurological toxicities.
- The most critical warning pertains to the high risk of agranulocytosis and neutropenia, which can be life-threatening.
- Consequently, patients receiving levamisole must undergo rigorous and frequent complete blood count (CBC) monitoring, including a differential, prior to and continuously throughout the treatment course.
- Therapy must be promptly discontinued or the dose significantly reduced upon observing a substantial decline in neutrophil counts (e.
- g.
- , below 1000 cells/mm³) or the emergence of clinical symptoms indicative of infection or agranulocytosis.
- Neurological adverse effects, encompassing encephalopathy, confusion, and peripheral neuropathy, have also been documented, with some instances proving irreversible.
- Caution is strongly advised in patients with pre-existing hematologic abnormalities, significant hepatic impairment, or renal dysfunction, as impaired organ function can detrimentally affect levamisole's metabolism and excretion, thereby escalating toxicity risk.
- Levamisole may induce a disulfiram-like reaction when consumed with alcohol and can potentially potentiate the effects of certain medications, such as phenytoin.
- Levamisole is classified as Pregnancy Category C; its use in pregnant or breastfeeding individuals should only be considered if the potential therapeutic benefits unequivocally outweigh the potential risks to the fetus or infant.
How it Works (Mechanism of Action)
The mechanism of action for levamisole is complex and exhibits distinct modalities depending on its intended therapeutic application. In its historical context as an immunomodulator, particularly in adjuvant colon cancer therapy, levamisole was believed to exert its effects by restoring depressed immune function rather than indiscriminately stimulating normal immune responses. It is thought to modulate various aspects of the immune system, including enhancing T-lymphocyte function, improving macrophage phagocytic activity, and optimizing neutrophil chemotaxis and adherence. While the precise molecular targets for its immunomodulatory effects are not entirely elucidated, it has been observed to effectively restore impaired delayed-type hypersensitivity reactions, thereby potentially bolstering the host's endogenous immune defenses against residual cancer cells or certain pathogens. As an anthelmintic agent, levamisole functions as a nicotinic acetylcholine receptor agonist in susceptible nematodes. This binding leads to continuous and sustained stimulation of the worm's neuromuscular junctions, resulting in spastic paralysis of the helminth musculature. The paralyzed worms subsequently lose their ability to maintain their position within the host's intestinal lumen and are then expelled from the body.